Features include sometimes findings: Prolonged QT interval, Syncope, and Sudden cardiac death; and rarely findings: Sinus bradycardia. 5 total HPO annotations.

ANK2 encodes ankyrin 2 (3,957 aa). Plays an essential role in the localization and membrane stabilization of ion transporters and ion channels in several cell types, including cardiomyocytes, as well as in striated muscle cells. Highest expression in Brain Cerebellum (96.7 TPM) and Brain Cerebellar Hemisphere (95.2 TPM).

Cardiac arrhythmia, ankyrin-B-related is associated with mutations in the ANK2 gene on chromosome 4.

ANK2 is classified as a druggable target (Ion Channel and Transporter categories) with score 1.4.

Genetic testing for ANK2 is available. Testing is considered confirmatory for diagnosis.

No clinical trials have been registered for cardiac arrhythmia, ankyrin-B-related.

4 publications have been identified in PubMed for cardiac arrhythmia, ankyrin-B-related. Research spans Review / Meta-Analysis (25%), Case Report / Case Series (25%), and Clinical Trial Publication (25%).

Recent Publications

• Maroofian R (2025). [PMID: 40879451](https://pubmed.ncbi.nlm.nih.gov/40879451/). *Movement disorders : official journal of the Movement Disorder Society*. [Clinical Trial Publication]

• Guo L (2025). [PMID: 39867173](https://pubmed.ncbi.nlm.nih.gov/39867173/). *Reviews in cardiovascular medicine*. [Review / Meta-Analysis]

• Lin PH (2025). [PMID: 39962910](https://pubmed.ncbi.nlm.nih.gov/39962910/). *Epilepsia open*. [Case Report / Case Series]

• Malhotra N (2025). [PMID: 40866040](https://pubmed.ncbi.nlm.nih.gov/40866040/). *JACC. Basic to translational science*. [Gene Therapy / Novel Therapeutics]